Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05083364 | Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease | PHASE1 | COMPLETED | 62 | — | — | Feb 1, 2022 | Sep 10, 2025 | May 22, 2026 | 16 | Australia, Georgia +5 |
| Arm | Type | Description |
|---|---|---|
| ARO-C3 (Healthy Volunteers) | EXPERIMENTAL | 1 or 2 doses of ARO-C3 by subcutaneous (sc) injection |
| Placebo (Healthy Volunteers) | PLACEBO_COMPARATOR | placebo calculated volume to match active treatment by sc injection |
| ARO-C3 (Adult Patients with C3G or IgAN) | EXPERIMENTAL | 3 doses of ARO-C3 by sc injection |
| Name | Type | Description |
|---|---|---|
| ARO-C3 | DRUG | ARO-C3 for sc injection |
| Placebo | DRUG | sterile normal saline (0.9% NaCl) for sc injection |
Inclusion Criteria (All Participants): * Willing to provide written informed consent and to comply with study requirements * Female participants must be non-pregnant/non-lactating * Healthy volunteers must be willing to be vaccinated with a meningococcal and pneumococcal vaccine. C3G and IgAN parti...